EW Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of 26.43% compared to Edwards Lifesciences's net margin of -1230.55%. Edwards Lifesciences's return on equity of 55.09% beat NeuroOne Medical Technologies's return on equity of -335.54%.

Edwards Lifesciences has a consensus price target of $79.51, signalling upside risk potential of 7.97%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 75.44%. Given that NeuroOne Medical Technologies has higher upside potential than Edwards Lifesciences, analysts believe NeuroOne Medical Technologies is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.113, which suggesting that the stock is 11.273% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.512%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than NeuroOne Medical Technologies quarterly revenues of $272.3K. Edwards Lifesciences's net income of $3.1B is higher than NeuroOne Medical Technologies's net income of -$3.4M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.63x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 6.73x versus 8.84x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 26.43% compared to Edwards Lifesciences's net margin of -211%. Edwards Lifesciences's return on equity of 55.09% beat Nutriband's return on equity of -69.58%.

Edwards Lifesciences has a consensus price target of $79.51, signalling upside risk potential of 7.97%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 304.49%. Given that Nutriband has higher upside potential than Edwards Lifesciences, analysts believe Nutriband is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.113, which suggesting that the stock is 11.273% more volatile than S&P 500. In comparison Nutriband has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.406%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than Nutriband quarterly revenues of $645.8K. Edwards Lifesciences's net income of $3.1B is higher than Nutriband's net income of -$1.4M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.63x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 6.73x versus 21.81x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of 26.43% compared to Edwards Lifesciences's net margin of --. Edwards Lifesciences's return on equity of 55.09% beat enVVeno Medical's return on equity of --.

Edwards Lifesciences has a consensus price target of $79.51, signalling upside risk potential of 7.97%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 430.97%. Given that enVVeno Medical has higher upside potential than Edwards Lifesciences, analysts believe enVVeno Medical is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.113, which suggesting that the stock is 11.273% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.206, suggesting its more volatile than the S&P 500 by 20.612%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than enVVeno Medical quarterly revenues of --. Edwards Lifesciences's net income of $3.1B is higher than enVVeno Medical's net income of -$5.6M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.63x while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 6.73x versus 289.12x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of 26.43% compared to Edwards Lifesciences's net margin of -1700%. Edwards Lifesciences's return on equity of 55.09% beat SINTX Technologies's return on equity of -132.95%.

Edwards Lifesciences has a consensus price target of $79.51, signalling upside risk potential of 7.97%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 1756.76%. Given that SINTX Technologies has higher upside potential than Edwards Lifesciences, analysts believe SINTX Technologies is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.113, which suggesting that the stock is 11.273% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.492, suggesting its more volatile than the S&P 500 by 49.157%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than SINTX Technologies quarterly revenues of $367K. Edwards Lifesciences's net income of $3.1B is higher than SINTX Technologies's net income of -$6.2M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.63x while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 6.73x versus 1.03x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.